TNGX · Tango Therapeutics, Inc. · Executive Compensation
$21.93
-0.78 (-3.43%)
At close · Nov 20
Return incl. dividend (before tax)
Market Cap
$3.85B
Shares
169.46M
Volume · Nov 20
932.36K
Avg daily vol (3M)
3.41M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Barbara Weber | Executive Chairman | $2,823,992 |
| Adam Crystal | M.D., Ph.D. President of Research and Development | $1,721,080 |
| Daniella Beckman | Former Chief Financial Officer | $1,155,775 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Barbara Weber | President, Chief Executive Officer and Director | $6,541,200 |
| Adam Crystal | M.D., Ph.D. President of Research and Development | $3,777,318 |
| Daniella Beckman | Chief Financial Officer | $3,166,290 |
| Douglas Barry | Chief Legal Officer | $2,094,450 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Barbara Weber | President, Chief Executive Officer and Director | $3,391,059 |
| Adam Crystal | M.D., Ph.D. President of Research and Development | $3,110,646 |
| Alan Huang | Former Chief Scientific Officer | $1,770,905 |
| Daniella Beckman | Chief Financial Officer | $1,522,744 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Barbara Weber | President, Chief Executive Officer and Director | $4,681,787 |
| Alan Huang | Former Chief Scientific Officer | $1,818,901 |
| Daniella Beckman | Chief Financial Officer | $1,516,879 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Barbara Weber | President, Chief Executive Officer and Director | $11,515,974 |
| Daniella Beckman | Chief Financial Officer | $3,176,664 |
| Alan Huang | Chief Scientific Officer | $2,215,657 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Barbara Weber | President, Chief Executive Officer and Director | $958,221 |
| Daniella Beckman | Chief Financial Officer | $834,374 |
| Alan Huang | Chief Scientific Officer | $589,517 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
|
Barbara Weber
“Dr. Weber’s resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, practices or policies.”
|
member of Company's board of directors | Resigned | 2026-08-06 |
|
Barbara Weber
“Dr. Weber’s resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, practices or policies.”
|
Executive Chair | Terminated | 2026-08-06 |
| Robert Azelby | director of the Company | Appointed | 2026-06-23 |
| Sung Lee | Lead Independent Director | Appointed | 2026-05-13 |
|
Kanishka Pothula
“Mr. Pothula’s resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, practices or policies.”
|
Board of Directors | Resigned | 2026-05-13 |
|
Alexis Borisy
“Mr. Borisy’s resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, practices or policies.”
|
Board of Directors | Resigned | 2026-05-13 |
| Daniella Beckman | Chief Financial Officer, principal accounting officer and principal financial officer | Terminated | 2026-05-08 |
| Janice Kapty | SVP, Corporate Strategy and Project Leadership | Appointed | 2026-04-15 |
| Yen-Ching Chua | Chief Development Operations Officer | Appointed | 2026-04-15 |
| Jessica Newcomb | principal accounting officer | Appointed | 2026-04-15 |
| Matthew Gall | Chief Financial Officer | Appointed | 2026-04-15 |
|
Barbara Weber, M.D.
“Dr. Weber's resignation as President and Chief Executive Officer and transition is not the result of any disagreement with respect to the Company's operations, policies, or practices.”
|
Chief Executive Officer | Retired | 2026-01-08 |
| Malte Peters | President and Chief Executive Officer | Appointed | 2026-01-08 |
|
Barbara Weber
“Dr. Weber's resignation as President and Chief Executive Officer and transition is not the result of any disagreement with respect to the Company's operations, policies, or practices.”
|
Chief Executive Officer | Retired | 2026-01-08 |
| Malte Peters, M.D. | President and Chief Executive Officer | Appointed | 2026-01-08 |
| Barbara Weber, M.D. | Executive Chair | Appointed | 2026-01-08 |
| Sung H. Lee | director | Appointed | 2026-01-05 |
| Douglas Barry | Chief Legal and Compliance Officer and Corporate Secretary | Resigned | 2025-08-25 |
| John Ketchum | director of the Company | Appointed | 2023-08-30 |
|
Aaron Davis
“Mr. Davis has indicated that his departure from the Board was not the result of any disagreement with management or the Board or on any matter relating to the Company’s operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2023-08-30 |
| Jannik Andersen | Chief Scientific Officer | Appointed | 2023-08-07 |
| Adam Crystal, M.D., Ph.D. | President, Research & Development | Appointed | 2023-02-28 |
| Barbara Weber | Class III director | Appointed | 2021-08-13 |
| Aaron Davis | Class III director | Appointed | 2021-08-13 |
| Mace Rothenberg | Class II director | Appointed | 2021-08-13 |
Leadership
- Malte Peters CEO, Board Member
- Malte Peters, M.D. CEO
- Barbara Weber Chairman, Board Member
- Barbara Weber, M.D. Chairman
- Matthew Gall CFO
- Douglas Barry General Counsel
- Jessica Newcomb Chief Accounting Officer
- Aaron Davis Board Member
- Alexis Borisy Board Member
- James B. Avery Board Member
- John Ketchum Board Member
- Lesley Ann Calhoun Board Member
- Lesley Calhoun Board Member
- Mace Rothenberg Board Member
- Robert Azelby Board Member
- Sung H. Lee Board Member
- Sung Lee Board Member
Key facts
CIK
1819133
CUSIP
87583X109
13F (30d)
267 filings
250 filers
Visit website
Investor relations